Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)
SRA-MMB-4365/219627
Phase 2 other active
Quick answer
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF) for Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) is a Phase 2 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
- Phase
- Phase 2
- Modality
- other
- Status
- active